UNLABELLED: IRAK-4 deficiency causes IL-1R and TLR signaling failure, resulting in minimal clinical features despite invasive bacterial infection. We report the course of a 7-year-old IRAK-4-deficient girl presenting in the first year with multiple occult Staphylococcus aureus lymphadenitis. She was managed with antibiotic prophylaxis (sulfa/trimethoprim/PenV, then - due to neutropenia - Cefprozil), pneumococcal vaccination (PCV-7, Pneumovax23, PCV-13) and vigilance. Pneumococcal-specific IgG levels were monitored. No bacterial infections occurred on prophylaxis for 6 years after initial presentation. IgG response to pneumococcal polysaccharide was satisfactory but short-lived, requiring frequent boosting. At age 7, patient developed a morning headache and vomited once. Cefprozil was administered and re-dosed. Over 12 h, she was fatigued without other symptoms. Low fever accompanied another emesis. A few hours later she was confused, and purpuric rash appeared. Emergency physicians diagnosed sepsis/meningitis and started vancomycin-ceftriaxone. Respiratory failure and cerebellar herniation occurred <24 h after first symptoms. Blood and CSF grew Streptococcus pneumoniae type 6C resistant to second-generation cephalosporins. The patient's latest PCV-13 vaccination was 6 weeks before death, which included serotype 6A. Immunoglobulins were normal except IgG4 was increased (3.4 g/L). IgG response to vaccine antigens was satisfactory. IgG to 6A is reported to cross-react with 6C, but this was not the case here. CONCLUSION: Despite antibiotic prophylaxis and repeated vaccination, even older IRAK-4-deficient patients are at high risk of rapidly fatal infection due to emergence of antibiotic resistance. These patients need early assessment at any age, bacterial culturing, alternative empiric antibiotic therapy and close observation when even vaguely unwell. Based on increasingly recognized immunological and/or clinical impairments in B cell function, and possibly other defects, long-term IgG prophylaxis in addition to antibiotics is recommended.
UNLABELLED: IRAK-4 deficiency causes IL-1R and TLR signaling failure, resulting in minimal clinical features despite invasive bacterial infection. We report the course of a 7-year-old IRAK-4-deficient girl presenting in the first year with multiple occult Staphylococcus aureus lymphadenitis. She was managed with antibiotic prophylaxis (sulfa/trimethoprim/PenV, then - due to neutropenia - Cefprozil), pneumococcal vaccination (PCV-7, Pneumovax23, PCV-13) and vigilance. Pneumococcal-specific IgG levels were monitored. No bacterial infections occurred on prophylaxis for 6 years after initial presentation. IgG response to pneumococcal polysaccharide was satisfactory but short-lived, requiring frequent boosting. At age 7, patient developed a morning headache and vomited once. Cefprozil was administered and re-dosed. Over 12 h, she was fatigued without other symptoms. Low fever accompanied another emesis. A few hours later she was confused, and purpuric rash appeared. Emergency physicians diagnosed sepsis/meningitis and started vancomycin-ceftriaxone. Respiratory failure and cerebellar herniation occurred <24 h after first symptoms. Blood and CSF grew Streptococcus pneumoniae type 6C resistant to second-generation cephalosporins. The patient's latest PCV-13 vaccination was 6 weeks before death, which included serotype 6A. Immunoglobulins were normal except IgG4 was increased (3.4 g/L). IgG response to vaccine antigens was satisfactory. IgG to 6A is reported to cross-react with 6C, but this was not the case here. CONCLUSION: Despite antibiotic prophylaxis and repeated vaccination, even older IRAK-4-deficient patients are at high risk of rapidly fatal infection due to emergence of antibiotic resistance. These patients need early assessment at any age, bacterial culturing, alternative empiric antibiotic therapy and close observation when even vaguely unwell. Based on increasingly recognized immunological and/or clinical impairments in B cell function, and possibly other defects, long-term IgG prophylaxis in addition to antibiotics is recommended.
Authors: Capucine Picard; Horst von Bernuth; Pegah Ghandil; Maya Chrabieh; Ofer Levy; Peter D Arkwright; Douglas McDonald; Raif S Geha; Hidetoshi Takada; Jens C Krause; C Buddy Creech; Cheng-Lung Ku; Stephan Ehl; László Maródi; Saleh Al-Muhsen; Sami Al-Hajjar; Abdulaziz Al-Ghonaium; Noorbibi K Day-Good; Steven M Holland; John I Gallin; Helen Chapel; David P Speert; Carlos Rodriguez-Gallego; Elena Colino; Ben-Zion Garty; Chaim Roifman; Toshiro Hara; Hideto Yoshikawa; Shigeaki Nonoyama; Joseph Domachowske; Andrew C Issekutz; Mimi Tang; Joanne Smart; Simona Eva Zitnik; Cyrille Hoarau; Dinakantha S Kumararatne; Adrian J Thrasher; E Graham Davies; Claire Bethune; Nicolas Sirvent; Dominique de Ricaud; Yildiz Camcioglu; Júlia Vasconcelos; Margarida Guedes; Artur Bonito Vitor; Carlos Rodrigo; Francisco Almazán; Maria Méndez; Juan Ignacio Aróstegui; Laia Alsina; Claudia Fortuny; Janine Reichenbach; James W Verbsky; Xavier Bossuyt; Rainer Doffinger; Laurent Abel; Anne Puel; Jean-Laurent Casanova Journal: Medicine (Baltimore) Date: 2010-11 Impact factor: 1.889
Authors: Jeannette L Comeau; Tong-Jun Lin; Marian B Macken; Bo Li; Cheng-Lung Ku; Horst von Bernuth; Jean-Laurent Casanova; Andrew C Issekutz Journal: Pediatr Infect Dis J Date: 2008-02 Impact factor: 2.129
Authors: Capucine Picard; Anne Puel; Marion Bonnet; Cheng-Lung Ku; Jacinta Bustamante; Kun Yang; Claire Soudais; Stéphanie Dupuis; Jacqueline Feinberg; Claire Fieschi; Carole Elbim; Remi Hitchcock; David Lammas; Graham Davies; Abdulaziz Al-Ghonaium; Hassan Al-Rayes; Sulaiman Al-Jumaah; Sami Al-Hajjar; Ibrahim Zaid Al-Mohsen; Husn H Frayha; Rajivi Rucker; Thomas R Hawn; Alan Aderem; Haysam Tufenkeji; Soichi Haraguchi; Noorbibi K Day; Robert A Good; Marie-Anne Gougerot-Pocidalo; Adrian Ozinsky; Jean-Laurent Casanova Journal: Science Date: 2003-03-13 Impact factor: 47.728
Authors: Bing He; Raul Santamaria; Weifeng Xu; Montserrat Cols; Kang Chen; Irene Puga; Meimei Shan; Huabao Xiong; James B Bussel; April Chiu; Anne Puel; Jeanine Reichenbach; László Marodi; Rainer Döffinger; Julia Vasconcelos; Andrew Issekutz; Jens Krause; Graham Davies; Xiaoxia Li; Bodo Grimbacher; Alessandro Plebani; Eric Meffre; Capucine Picard; Charlotte Cunningham-Rundles; Jean-Laurent Casanova; Andrea Cerutti Journal: Nat Immunol Date: 2010-08-01 Impact factor: 25.606
Authors: Kirsten Kuipers; Kristen L Lokken; Tonia Zangari; Mark A Boyer; Sunny Shin; Jeffrey N Weiser Journal: PLoS Pathog Date: 2018-10-31 Impact factor: 6.823
Authors: Karina A Top; Wendy Vaudry; Shaun K Morris; Anne Pham-Huy; Jeffrey M Pernica; Bruce Tapiéro; Soren Gantt; Victoria E Price; S Rod Rassekh; Lillian Sung; Athena McConnell; Earl Rubin; Rupesh Chawla; Scott A Halperin Journal: Clin Infect Dis Date: 2020-12-03 Impact factor: 9.079